Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04260217
Title APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenstrom Macroglobulinemia (MAPLE-1)
Acronym MAPLE-1
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ascentage Pharma Group Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS

Facility Status City State Zip Country Details
City of Hope Duarte California 91010 United States Details
Colorado Blood Cancer Institute Denver Colorado 80218 United States Details
Mayo Clinic Jacksonville Florida 32224 United States Details
Weill Cornell Univ Hospitals New York New York 10065 United States Details
MD Anderson Houston Texas 77030 United States Details
St. Vincent Hospital Melbourne 3065 Australia Details
Nanfang Hospital Guangzhou Guangdong China Details
Zhongshan Hospital of Fudan University Shanghai Shanghai China Details
Beijing Chaoyang Hospital Beijing China Details
The First Affiliated Hospital,College Of Medicine,Zhejiang University Hangzhou China Details
The First Affiliated Hospital with Nanjing Medical University Nanjing China Details
The First Affiliated Hospital Of Soochow University Suzhou China Details
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences Tianjin China Details
Henan Cancer Hospital Zhengzhou China Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field